ZYDUSLIFE.BO
Zydus Lifesciences LimitedExplain this page
Arphra AIPlain-English read on Zydus Lifesciences Limited’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
A snapshot of the latest fiscal year’s margins, returns on capital, balance-sheet strength and efficiency, computed from the income statement, balance sheet and cash-flow rows. Source income / balance / cash_flow.
Valuation multiples
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Headline | |||
| Market cap | $1.01T | $883.06B | $876.59B |
| Enterprise value | $1.02T | $906.93B | $987.39B |
| Multiples | |||
| P / E | — | — | — |
| P / B | — | — | — |
| EV / EBITDA | — | — | — |
| EV / Sales | 5.20 | 3.90 | 3.64 |
| EV / FCF | 43.75 | 17.91 | -82.10 |
| Yields | |||
| Earnings yield | +3.81% | +5.12% | +5.75% |
| Free cash flow yield | +2.29% | +5.73% | -1.37% |
| Dividend yield | — | — | — |
Profitability
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Margins | |||
| Gross margin | +67.29% | +71.87% | +51.68% |
| Operating margin | +38.86% | +41.32% | +21.31% |
| EBITDA margin | +26.89% | +29.39% | +31.55% |
| EBIT margin | +23.22% | +25.64% | +26.36% |
| Pre-tax margin | +25.21% | +26.18% | +24.75% |
| Net margin | +19.74% | +19.47% | +18.56% |
| Cost structure | |||
| Cost of revenue / sales | +32.71% | +28.13% | +48.32% |
| R&D intensity | +6.71% | +8.37% | +8.37% |
| SG&A intensity | +21.72% | +22.18% | +21.99% |
| Effective tax rate | +19.84% | +23.20% | +23.74% |
Returns on capital
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Returns | |||
| Return on equity (ROE) | +17.46% | +17.17% | +17.04% |
| Return on assets (ROA) | +13.18% | +12.16% | +9.62% |
| Return on capital (ROC) | +33.16% | +32.48% | +13.75% |
| Return on invested capital (ROIC) | +16.85% | +15.30% | +11.98% |
| Asset turnover | +66.76% | +62.47% | +51.80% |
| DuPont · ROE decomposition | |||
| Net margin | +19.74% | +19.47% | +18.56% |
| Asset turnover (× revenue / assets) | +66.76% | +62.47% | +51.80% |
| Equity multiplier (× assets / equity) | +132.48% | +141.14% | +177.16% |
Activity & efficiency
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Turnover | |||
| Asset turnover | 0.67 | 0.62 | 0.52 |
| Fixed-asset turnover | 2.83 | 3.16 | 2.61 |
| Inventory turnover | 1.86 | 1.66 | 2.33 |
| Receivables turnover | 3.56 | 5.07 | 5.01 |
| Payables turnover | 3.01 | 2.84 | 4.61 |
| Days outstanding | |||
| Days sales outstanding (DSO) | 102.44 | 72.00 | 72.86 |
| Days inventory outstanding (DIO) | 196.49 | 220.17 | 156.59 |
| Days payables outstanding (DPO) | 121.41 | 128.72 | 79.16 |
| Cash conversion cycle | 177.52 | 163.45 | 150.29 |
Cash flow quality
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Operating CF / Net income | 0.83 | 1.50 | 0.43 |
| FCF / Net income | 0.60 | 1.12 | -0.24 |
| FCF margin | +11.88% | +21.79% | -4.43% |
| OCF margin | +16.35% | +29.16% | +8.07% |
| CapEx / Revenue | +4.64% | +7.37% | +12.50% |
| CapEx / D&A | 1.19 | 1.87 | 2.41 |
| Stock-based comp / Revenue | 0.00% | 0.00% | 0.00% |
Per-share & shareholder yield
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| EPS · diluted | 37.91 | 44.97 | 50.09 |
| EPS · basic | 37.91 | 44.97 | 50.09 |
| Book value / share | 218.41 | 261.92 | 294.00 |
| Tangible BV / share | 140.57 | 177.80 | 120.99 |
| Sales / share | 193.17 | 230.95 | 269.81 |
| Operating CF / share | 31.59 | 67.34 | 21.78 |
| Free cash flow / share | 22.94 | 50.32 | -11.95 |
| Dividends / share | 6.14 | 3.01 | 10.99 |
| Payout ratio | +16.09% | +6.68% | +21.95% |
| Retention ratio | +83.91% | +93.32% | +78.05% |
Growth
| In USD | FY 2024 | FY 2025 | FY 2026 | 2y CAGR |
|---|---|---|---|---|
| Top-line | ||||
| Revenue · YoY | — | +18.90% | +16.81% | +17.85% |
| Gross profit · YoY | — | +26.98% | -16.00% | +3.28% |
| Profit | ||||
| Operating income · YoY | — | +26.44% | -39.75% | -12.72% |
| EBITDA · YoY | — | +29.92% | +25.40% | +27.64% |
| Net income · YoY | — | +17.26% | +11.37% | +14.27% |
| Operating | ||||
| EBIT · YoY | — | +31.31% | +20.08% | +25.57% |
| R&D · YoY | — | +48.18% | +16.88% | +31.60% |
| Per-share | ||||
| EPS · diluted · YoY | — | +18.62% | +11.39% | +14.95% |
| EPS · basic · YoY | — | +18.62% | +11.39% | +14.95% |
Credit & leverage
| In USD | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Leverage | |||
| Total debt | $8.04B | $32.13B | $124.96B |
| Net debt | $3.91B | $23.86B | $110.79B |
| Net debt / EBITDA | 0.07 | 0.35 | 1.29 |
| Debt / equity | 0.04 | 0.12 | 0.42 |
| Debt / assets | +2.75% | +8.64% | +23.84% |
| Equity / assets | +75.48% | +70.85% | +56.45% |
| Coverage | |||
| EBITDA / interest expense | 106.85 | 68.78 | 19.51 |
| Operating income / interest | 154.38 | 96.71 | 13.18 |
| Interest expense | $492M | $993M | $4.39B |
| Liquidity | |||
| Current ratio | 2.14 | 1.89 | 1.27 |
| Quick ratio | 1.29 | 1.37 | 0.80 |
| Cash ratio | 0.08 | 0.09 | 0.09 |
| Working capital | $60.78B | $80.05B | $41.94B |
| Working capital / revenue | +31.09% | +34.44% | +15.45% |
Historical multiples · μ ± σ bands
3 fiscal-year-end observations from key_metrics. Mean is dashed; light-green band is ±1σ, light-red band ±2σ. The dot marks the most recent value; the cheap / fair / rich verdict uses z-score against the issuer's own history (yields inverted — a high yield is cheap).
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| P / E | — | — | — |
| P / B | — | — | — |
| EV / EBITDA | — | — | — |
| EV / Sales | 3.64x | 3.90x | 5.20x |
| Earnings yield | 5.7% | 5.1% | 3.8% |
| FCF yield | -1.4% | 5.7% | 2.3% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| ROE | 18.6% | 18.9% | 19.5% |
| ROA | 9.6% | 12.2% | 13.2% |
| ROIC | 9.7% | 23.5% | 24.6% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / equity | — | — | — |
| Net debt / EBITDA | 1.29 | 0.35 | 0.07 |
| Interest coverage | — | — | — |
| Current ratio | 1.27x | 1.89x | 2.14x |
| Quick ratio | — | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).